A new trading day began on Monday, with Beam Therapeutics Inc (NASDAQ: BEAM) stock price down -4.71% from the previous day of trading, before settling in for the closing price of $26.34. BEAM’s price has ranged from $20.84 to $45.05 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 43280.87%. Meanwhile, its annual earnings per share averaged -9.24%. With a float of $73.69 million, this company’s outstanding shares have now reached $83.63 million.
Considering the fact that the conglomerate employs 483 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 74.05%, operating margin of -654.25%, and the pretax margin is -593.06%.
Beam Therapeutics Inc (BEAM) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 11.95%, while institutional ownership is 83.37%. The most recent insider transaction that took place on Feb 18 ’25, was worth 220,045. In this transaction SVP, Finance and Treasurer of this company sold 6,287 shares at a rate of $35.00, taking the stock ownership to the 37,527 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Legal Officer sold 10,000 for $34.00, making the entire transaction worth $340,000. This insider now owns 102,968 shares in total.
Beam Therapeutics Inc (BEAM) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.49% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Here are Beam Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 33.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.58, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -5.01 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Compared to the last year’s volume of 1.3 million, its volume of 1.46 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 3.53%. Additionally, its Average True Range was 2.21.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 28.09%, which indicates a significant increase from 2.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.04% in the past 14 days, which was higher than the 72.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.17, while its 200-day Moving Average is $25.73. Nevertheless, the first resistance level for the watch stands at $26.29 in the near term. At $27.49, the stock is likely to face the second major resistance level. The third major resistance level sits at $28.23. If the price goes on to break the first support level at $24.35, it is likely to go to the next support level at $23.61. Now, if the price goes above the second support level, the third support stands at $22.41.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
With a market capitalization of 2.10 billion, the company has a total of 83,688K Shares Outstanding. Currently, annual sales are 377,710 K while annual income is -132,530 K. The company’s previous quarter sales were 14,270 K while its latest quarter income was -96,670 K.
